Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Recruiting Phase 3 Interventional

Pediatric Dose Optimization for Seizures in Emergency Medical Services

NCT05121324
View directory record Official record
Conditions
Seizures
Interventions
Standardized seizure protocol, Conventional seizure protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 13 Years
Enrollment
6,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wear-Time Trial for Self-Fitting Hearing Aid

NCT04823494
View directory record Official record
Conditions
Hearing Loss, Sensorineural
Interventions
Hearing aids
Device
Lead sponsor
GN Hearing A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Palos Hills, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

NCT00232596
View directory record Official record
Conditions
Seizures
Interventions
Retigabine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Birmingham, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 2Phase 3 Interventional

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902
View directory record Official record
Conditions
Focal Seizure
Interventions
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode

NCT01417078
View directory record Official record
Conditions
Epilepsy
Interventions
Diazepam
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Phoenix, Arizona • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 23, 2026, 7:50 AM EDT
Enrolling by invitation Phase 3 Interventional

An Open-label Study of XEN1101 in Epilepsy

NCT05718817
View directory record Official record
Conditions
Focal Epilepsy, Tonic-Clonic Seizures
Interventions
XEN1101
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
54
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 7:50 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Sedline 4 Channel Electroencephalogram (EEG) Monitoring During Suppression of Unilateral Hemispheric Function (Wada Test

NCT02503878
View directory record Official record
Conditions
Seizure
Interventions
Masimo Sedline brain function monitors
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 23, 2026, 7:50 AM EDT
Recruiting Phase 3 Interventional

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

NCT05219617
View directory record Official record
Conditions
Seizures, Lennox Gastaut Syndrome
Interventions
Carisbamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
22
States / cities
Palo Alto, California • Jacksonville, Florida • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

NCT01339559
View directory record Official record
Conditions
Epilepsy
Interventions
Brivaracetam
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
49
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 23, 2026, 7:50 AM EDT
Active, not recruiting Phase 4 Interventional

Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy

NCT06453213
View directory record Official record
Conditions
Focal Onset Seizure
Interventions
Cenobamate
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Not applicable Interventional Results available

The Effect on Cognition of Terminating ECT Induced Seizures With Propofol

NCT00616759
View directory record Official record
Conditions
Major Depression
Interventions
electroconvulsive therapy, electroconvulsive therapy plus propofol, propofol
Procedure · Drug
Lead sponsor
Loma Linda University
Other
Eligibility
45 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

NCT02929667
View directory record Official record
Conditions
Epilepsy, SUDEP
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Rup Kamal Sainju
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

NCT05067634
View directory record Official record
Conditions
Partial Epilepsy
Interventions
Xcopri
Drug
Lead sponsor
SK Life Science, Inc.
Industry
Eligibility
2 Years to 18 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Palo Alto, California • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 7:50 AM EDT
Terminated Phase 3 Interventional Results available

Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

NCT02834793
View directory record Official record
Conditions
Lennox-Gastaut Syndrome (LGS)
Interventions
Placebo, Perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
31
States / cities
Little Rock, Arkansas • Palo Alto, California • Gulf Breeze, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Not applicable Interventional

Reduction and Prevention of Seizure Occurrence From Exposure to Auditory Stimulation in Individuals With Neurological Handicaps

NCT01459692
View directory record Official record
Conditions
Seizures, Epilepsy
Interventions
Music Exposure
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
5 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 23, 2026, 7:50 AM EDT
Withdrawn Phase 2 Interventional

Efficacy of Keppra in Acute Alcohol Related Seizure Control--A Pilot Study

NCT00627133
View directory record Official record
Conditions
Seizure, Alcohol Related
Interventions
levetiracetam
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 23, 2026, 7:50 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Refractory Status Epilepticus

NCT00265616
View directory record Official record
Conditions
Status Epilepticus
Interventions
propofol, thiopental/pentobarbital
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask

NCT04979858
View directory record Official record
Conditions
Covid19, SARS-CoV2 Infection
Interventions
Focal Mask
Device
Lead sponsor
Georgia Institute of Technology
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

NCT00699972
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
E2007 (perampanel), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 99 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2020 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

NCT02324673
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 3 Interventional Results available

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

NCT02721069
View directory record Official record
Conditions
Acute Repetitive Seizures, Breakthrough Seizures
Interventions
NRL-1
Drug
Lead sponsor
Neurelis, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Little Rock, Arkansas • Rochester, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Oct 23, 2026, 7:50 AM EDT
Completed No phase listed Observational

Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants

NCT05438641
View directory record Official record
Conditions
Alcohol Withdrawal Syndrome
Interventions
BZDP-Sparing Protocol, BZDP-Based Protocol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 23, 2026, 7:50 AM EDT
Completed No phase listed Observational

Artificial Intelligence-based Video Analysis to Detect Infantile Spasms

NCT06315829
View directory record Official record
Conditions
Infantile Spasms
Interventions
Spasm Vision
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 2 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 23, 2026, 7:50 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs

NCT01527006
View directory record Official record
Conditions
Central Nervous System
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Gulf Breeze, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 23, 2026, 7:50 AM EDT